Molecular Mechanisms of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a devastating disease that is precipitated by hypertrophic pulmonary vascular remodeling of distal arterioles to increase pulmonary artery pressure and pulmonary vascular resistance in the absence of left heart, lung parenchymal, or thromboembolic disease. Despite available medical therapy, pulmonary artery remodeling and its attendant hemodynamic consequences result in right ventricular dysfunction, failure, and early death. To limit morbidity and mortality, attention has focused on identifying the cellular and molecular mechanisms underlying aberrant pulmonary artery remodeling to identify pathways for intervention. While there is a well-recognized heritable genetic component to PAH, there is also evidence of other genetic perturbations, including pulmonary vascular cell DNA damage, activation of the DNA damage response, and variations in microRNA expression. These findings likely contribute, in part, to dysregulation of proliferation and apoptosis signaling pathways akin to what is observed in cancer; changes in cellular metabolism, metabolic flux, and mitochondrial function; and endothelial-to-mesenchymal transition as key signaling pathways that promote pulmonary vascular remodeling. This review will highlight recent advances in the field with an emphasis on the aforementioned molecular mechanisms as contributors to the pulmonary vascular disease pathophenotype.

• Publication year

  2016

• Venue

  International Journal of Molecular Sciences

• Publication date

  2016-05-01

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.3390/ijms17050761PMID 27213345PMCID 4881582
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intratracheal Gene Delivery of SERCA2a Ameliorates Chronic Post-Capillary Pulmonary Hypertension: A Large Animal Model.

  2016cited by this paper
• Endothelial Plasticity: Shifting Phenotypes through Force Feedback

  2016cited by this paper
• Regulation and Function of miR-214 in Pulmonary Arterial Hypertension

  2016cited by this paper
• Downregulation of MicroRNA-126 Contributes to the Failing Right Ventricle in Pulmonary Arterial Hypertension

  2015cited by this paper
• Genetic and hypoxic alterations of the microRNA-210-ISCU1/2 axis promote iron–sulfur deficiency and pulmonary hypertension

  2015cited by this paper
• The zinc transporter, ZIP12, regulates the pulmonary vascular response to chronic hypoxia

  2015cited by this paper
• Endothelial-to-Mesenchymal Transition in Pulmonary Hypertension

  2015cited by this paper
• MicroRNAs in pulmonary arterial hypertension.

  2015cited by this paper
• Iron homeostasis and pulmonary hypertension: iron deficiency leads to pulmonary vascular remodeling in the rat.

  2015cited by this paper
• Increased Mutagen Sensitivity and DNA Damage in Pulmonary Arterial Hypertension.

  2015cited by this paper
• Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects

  2015influential reference
• Iron Homeostasis and Pulmonary Hypertension Iron Deficiency Leads to Pulmonary Vascular Remodeling in the Rat

  2015cited by this paper
• Chronic Hypoxia Increases Intracellular Ca(2+) Concentration via Enhanced Ca(2+) Entry Through Receptor-Operated Ca(2+) Channels in Pulmonary Venous Smooth Muscle Cells.

  2015cited by this paper
• Smooth muscle cell progenitors are primed to muscularize in pulmonary hypertension

  2015cited by this paper
• Endothelial to Mesenchymal Transition Contributes to Endothelial Dysfunction in Pulmonary Arterial Hypertension.

  2015cited by this paper
• Upregulated expression of STIM2, TRPC6, and Orai2 contributes to the transition of pulmonary arterial smooth muscle cells from a contractile to proliferative phenotype.

  2015cited by this paper
• Intravenous Iron Therapy in Patients with Idiopathic Pulmonary Arterial Hypertension and Iron Deficiency

  2015cited by this paper
• Endothelial Fate Mapping in Mice With Pulmonary Hypertension

  2014cited by this paper
• Stretch-induced Ca2+ signalling in vascular smooth muscle cells depends on Ca2+ store segregation.

  2014cited by this paper
• The MicroRNA-130/301 Family Controls Vasoconstriction in Pulmonary Hypertension*

  2014cited by this paper
• The Metabolic Theory of Pulmonary Arterial Hypertension

  2014cited by this paper
• Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension.

  2014cited by this paper
• Loss of bone morphogenetic protein receptor 2 is associated with abnormal DNA repair in pulmonary arterial hypertension.

  2014cited by this paper
• Stretch-induced Ca 2 1 signalling in vascular smooth muscle cells depends on Ca 2 1 store segregation

  2014cited by this paper
• Whole-exome sequencing reveals TopBP1 as a novel gene in idiopathic pulmonary arterial hypertension.

  2014cited by this paper
• [Relevant issues in the pathology and pathobiology of pulmonary hypertension].

  2014cited by this paper
• Characterization of right ventricular remodeling and failure in a chronic pulmonary hypertension model.

  2014cited by this paper
• Recapitulation of developing artery muscularization in pulmonary hypertension.

  2014cited by this paper
• Role for DNA Damage Signaling in Pulmonary Arterial Hypertension

  2014cited by this paper
• Early onset severe pulmonary arterial hypertension with 'two-hit' digenic mutations in both BMPR2 and KCNA5 genes.

  2014cited by this paper
• EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension

  2013cited by this paper
• Mitochondrial dynamics--mitochondrial fission and fusion in human diseases.

  2013cited by this paper
• Therapeutic Efficacy of AAV1.SERCA2a in Monocrotaline-Induced Pulmonary Arterial Hypertension

  2013cited by this paper
• Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension

  2013cited by this paper
• A novel channelopathy in pulmonary arterial hypertension.

  2013cited by this paper
• Pulmonary arterial hypertension: epidemiology and registries.

  2013cited by this paper
• Relevant issues in the pathology and pathobiology of pulmonary hypertension.

  2013cited by this paper
• Definitions and diagnosis of pulmonary hypertension.

  2013cited by this paper
• A novel channelopathy in pulmonary arterial hypertension.

  2013cited by this paper
• Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension.

  2013cited by this paper
• FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: therapeutic benefits of dichloroacetate

  2012cited by this paper
• Whole Exome Sequencing to Identify a Novel Gene (Caveolin-1) Associated With Human Pulmonary Arterial Hypertension

  2012cited by this paper
• A Role for miR-145 in Pulmonary Arterial Hypertension: Evidence From Mouse Models and Patient Samples

  2012cited by this paper
• Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland.

  2012cited by this paper
• Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension.

  2012cited by this paper
• Plexiform vasculopathy of severe pulmonary arterial hypertension and microRNA expression.

  2012influential reference
• MicroRNA-21 Integrates Pathogenic Signaling to Control Pulmonary Hypertension: Results of a Network Bioinformatics Approach

  2012cited by this paper
• Exosomes Mediate the Cytoprotective Action of Mesenchymal Stromal Cells on Hypoxia-Induced Pulmonary Hypertension

  2012cited by this paper
• Dynamin-Related Protein 1–Mediated Mitochondrial Mitotic Fission Permits Hyperproliferation of Vascular Smooth Muscle Cells and Offers a Novel Therapeutic Target in Pulmonary Hypertension

  2012cited by this paper
• Krüppel-like Factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension

  2011cited by this paper
• Role for miR-204 in human pulmonary arterial hypertension

  2011cited by this paper
• Epigenetic Attenuation of Mitochondrial Superoxide Dismutase 2 in Pulmonary Arterial Hypertension: A Basis for Excessive Cell Proliferation and a New Therapeutic Target

  2010cited by this paper
• Dynamic Changes in Lung MicroRNA Profiles During the Development of Pulmonary Hypertension due to Chronic Hypoxia and Monocrotaline

  2010influential reference
• Somatic chromosome abnormalities in the lungs of patients with pulmonary arterial hypertension.

  2010cited by this paper
• Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22α‐targeted overexpression of the serotonin transporter

  2009cited by this paper
• miR-145 and miR-143 Regulate Smooth Muscle Cell Fate Decisions

  2009cited by this paper
• Faculty Opinions recommendation of miR-145 and miR-143 regulate smooth muscle cell fate and plasticity.

  2009cited by this paper
• Interleukin-6 Modulates the Expression of the Bone Morphogenic Protein Receptor Type II Through a Novel STAT3–microRNA Cluster 17/92 Pathway

  2009cited by this paper
• Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster.

  2009cited by this paper
• Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer.

  2008cited by this paper
• The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted

  2007cited by this paper
• Alterations of cellular bioenergetics in pulmonary artery endothelial cells

  2007cited by this paper
• An Abnormal Mitochondrial–Hypoxia Inducible Factor-1&agr;–Kv Channel Pathway Disrupts Oxygen Sensing and Triggers Pulmonary Arterial Hypertension in Fawn Hooded Rats: Similarities to Human Pulmonary Arterial Hypertension

  2006cited by this paper
• Dichloroacetate Prevents and Reverses Pulmonary Hypertension by Inducing Pulmonary Artery Smooth Muscle Cell Apoptosis

  2004cited by this paper
• Mature Vascular Endothelium Can Give Rise to Smooth Muscle Cells via Endothelial-Mesenchymal Transdifferentiation: In Vitro Analysis

  2002cited by this paper
• Microsatellite Instability of Endothelial Cell Growth and Apoptosis Genes Within Plexiform Lesions in Primary Pulmonary Hypertension

  2001cited by this paper
• Familial and sporadic primary pulmonary hypertension is caused by BMPR2 gene mutations resulting in haploinsufficiency of the bone morphogenetic protein tùype II receptor.

  2001cited by this paper
• Minireview Micrornas: Tiny Regulators with Great Potential

  2001cited by this paper
• Fine mapping of PPH1, a gene for familial primary pulmonary hypertension, to a 3-cM region on chromosome 2q33.

  2000cited by this paper
• Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension

  2000cited by this paper
• Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha.

  1999cited by this paper
• Histopathology of pulmonary hypertension.

  1998cited by this paper
• Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension.

  1998cited by this paper
• Cell cycle--dependent expression of L- and T-type Ca2+ currents in rat aortic smooth muscle cells in primary culture.

  1996cited by this paper
• Histopathology of pulmonary hypertension.

  1972cited by this paper
• The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus.

  1963cited by this paper
• Oxidation of fatty acids and tricarboxylic acid cycle intermediates by isolated rat liver mitochondria.

  1949cited by this paper
• THE METABOLISM OF TUMORS

  1931cited by this paper
• THE METABOLISM OF TUMORS IN THE BODY

  1927cited by this paper

• Deciphering the Counterintuitive Role of Vascular Endothelial Growth Factor Signaling Pathways in Pulmonary Arterial Hypertension

  2026cites this paper
• tRF-31-PS5P4PW3FJHP inhibits hypoxia-induced proliferation of pulmonary artery endothelial cells by regulating EDN1 splicing via binding to LSM4.

  2025cites this paper
• Insulin-like growth factor family and its impact on pulmonary arterial hypertension: a review

  2025cites this paper
• Network toxicology and molecular docking to investigate the association of perfluorooctane sulfonate and pulmonary arterial hypertension via adverse outcome pathways.

  2025cites this paper
• FTO regulates the proliferation and apoptosis of pulmonary artery smooth muscle cells through m6A demethylation modification.

  2025cites this paper
• Identification of LDHA as a Potential Therapeutic Target for Pulmonary Hypertension Through Modulation of Endothelial‐To‐Mesenchymal Transition

  2025cites this paper
• The Role of Hydrogen Sulfide in the Regulation of the Pulmonary Vasculature in Health and Disease

  2025cites this paper
• Redox regulation of lung endothelial PERK, unfolded protein response (UPR) and proliferation via NOX1: Targeted inhibition as a potential therapy for PAH

  2025cites this paper
• Cyclic nucleotide phosphodiesterases as drug targets.

  2025cites this paper
• Impact of sodium-glucose cotransporter-2 inhibitors on pulmonary vascular cell function and arterial remodeling

  2025cites this paper
• Dysfunction in mitochondrial electron transport chain drives the pathogenesis of pulmonary arterial hypertension: insights from a multi-omics investigation

  2025cites this paper
• Integrating pharmacogenetics, multi‐omics and machine learning in the novel therapeutic view of pulmonary hypertension

  2025cites this paper
• The Effect of lncRNA in Vascular Smooth Muscle Cells of Pulmonary Hypertension

  2024cites this paper
• G6PD is a prognostic biomarker correlated with immune infiltrates in lung adenocarcinoma and pulmonary arterial hypertension

  2024cites this paper
• NCAM1 modulates the proliferation and migration of pulmonary arterial smooth muscle cells in pulmonary hypertension

  2024cites this paper
• Decoding the enigmatic estrogen paradox in pulmonary hypertension: delving into estrogen metabolites and metabolic enzymes

  2024cites this paper
• LncRNA MEG3 aggravates acute pulmonary embolism-induced pulmonary arterial hypertension by regulating miR-34a-3p/DUSP1 axis.

  2024cites this paper
• Isorhamnetin alleviates symptoms and inhibits oxidative stress levels in rats with pulmonary arterial hypertension

  2024cites this paper
• CircSSR1 regulates pyroptosis of pulmonary artery smooth muscle cells through parental protein SSR1 mediating endoplasmic reticulum stress

  2024cites this paper
• MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study

  2024cites this paper
• A case report of postpartum idiopathic pulmonary arterial hypertension

  2024cites this paper
• A peripheral system disease-Pulmonary hypertension.

  2024cites this paper
• o8G Site-Specifically Modified tRF-1-AspGTC: A Novel Therapeutic Target and Biomarker for Pulmonary Hypertension

  2024cites this paper
• Therapeutic potential of natural flavonoids in pulmonary arterial hypertension: A review.

  2024cites this paper
• RNA m6A methylation and regulatory proteins in pulmonary arterial hypertension

  2024cites this paper
• Circ-Ntrk2 acts as a miR-296-5p sponge to activate the TGF-β1/p38 MAPK pathway and promote pulmonary hypertension and vascular remodelling

  2023cites this paper
• Erythropoietin improves pulmonary hypertension by promoting the homing and differentiation of bone marrow mesenchymal stem cells in lung tissue

  2023cites this paper
• Targeting IL-11 system as a treatment of pulmonary arterial hypertension.

  2023cites this paper
• Impact of reduced apolipoprotein A-I levels on pulmonary arterial hypertension.

  2023cites this paper
• Bibliometric and visual analysis of hypoxic pulmonary hypertension from 2013 to 2022

  2023cites this paper
• Isogenic pairs of induced-pluripotent stem-derived endothelial cells identify DYRK1A/PPARG/EGR1 pathway is responsible for Down syndrome-associated pulmonary hypertension

  2023cites this paper
• Allicin, an Emerging Treatment for Pulmonary Arterial Hypertension: An Experimental Study

  2023cites this paper
• Molecular regulation and therapeutic implications of cell death in pulmonary hypertension

  2023cites this paper
• Metabolic reprogramming, oxidative stress, and pulmonary hypertension

  2023cites this paper
• Myeloid-derived suppressor cells and pulmonary hypertension

  2023cites this paper
• Bound Together: RNA Binding Protein Quaking, STAT3, and Pulmonary Vascular Remodeling

  2023cites this paper
• Epigallocatechin-3-Gallate Attenuates Myocardial Dysfunction via Inhibition of Endothelial-to-Mesenchymal Transition

  2023cites this paper
• New Drugs and Therapies in Pulmonary Arterial Hypertension

  2023cites this paper
• Pathogenesis of pulmonary hypertension caused by left heart disease

  2023cites this paper
• Attenuating endothelial leakiness with self-assembled DNA nanostructures for pulmonary arterial hypertension.

  2023cites this paper
• Epigenetic Mechanisms as Emerging Therapeutic Targets and Microfluidic Chips Application in Pulmonary Arterial Hypertension

  2022cites this paper
• Genes in pediatric pulmonary arterial hypertension and the most promising BMPR2 gene therapy

  2022cites this paper
• Journal Pre-proof Mediterranean G6PD variant mitigates expression of DNA methyltransferases and right heart pressure in experimental model of pulmonary hypertension

  2022cites this paper
• Mediterranean G6PD variant mitigates expression of DNA methyltransferases and right heart pressure in experimental model of pulmonary hypertension

  2022cites this paper
• Co-exposure of PM2.5 and high-fat diet induce lipid metabolism reprogramming and vascular remodeling.

  2022cites this paper
• Recent Advances in the Treatment of Pulmonary Arterial Hypertension

  2022cites this paper
• DNA-PKcs participated in hypoxic pulmonary hypertension

  2022cites this paper
• Integrating Epigenetics and Metabolomics to Advance Treatments for Pulmonary Arterial Hypertension.

  2022cites this paper
• Molecular Pathways in Pulmonary Arterial Hypertension

  2022influential citation
• Protective effects of calcyclin-binding protein against pulmonary vascular remodeling in flow-associated pulmonary arterial hypertension

  2022cites this paper
• Knockdown of HSP110 attenuates hypoxia-induced pulmonary hypertension in mice through suppression of YAP/TAZ-TEAD4 pathway

  2022cites this paper
• Immunohistochemical study of extracellular matrix protein expression and lung innervation in patients with pulmonary arterial hypertension

  2022cites this paper
• Radiation-induced cardiac side-effects: The lung as target for interacting damage and intervention

  2022cites this paper
• Apela gene therapy alleviates pulmonary hypertension in rats

  2022cites this paper
• Inhibition of IP3R3 attenuates endothelial to mesenchymal transition induced by TGF-β1 through restoring mitochondrial function.

  2022cites this paper
• Oxidative Stress and Antioxidative Therapy in Pulmonary Arterial Hypertension

  2022cites this paper
• A Brief Review on Gender Differences in Mexican-Mestizo Patients with Pulmonary Arterial Hypertension (PAH) at a Tertiary-Level Hospital.

  2022cites this paper
• Differences in the expression of DNA methyltransferases and demethylases in leukocytes and the severity of pulmonary arterial hypertension between ethnic groups

  2022cites this paper
• Signal Transduction during Metabolic and Inflammatory Reprogramming in Pulmonary Vascular Remodeling

  2022cites this paper
• Dysregulation of the Nitric Oxide/Dimethylarginine Pathway in Hypoxic Pulmonary Vasoconstriction—Molecular Mechanisms and Clinical Significance

  2022cites this paper
• Bioactivities and mechanisms of natural medicines in the management of pulmonary arterial hypertension

  2022cites this paper
• New developments in the biology of fibroblast growth factors.

  2022cites this paper
• The Role of JAK/STAT Molecular Pathway in Vascular Remodeling Associated with Pulmonary Hypertension

  2021cites this paper
• Genetic Delivery and Gene Therapy in Pulmonary Hypertension

  2021cites this paper
• Effects of chronic moderate alcohol consumption on right ventricle and pulmonary remodelling

  2021cites this paper
• mTOR Signaling in Pulmonary Vascular Disease: Pathogenic Role and Therapeutic Target

  2021cites this paper
• SEDT2/METTL14-mediated m6A methylation awakening contributes to hypoxia-induced pulmonary arterial hypertension in mice

  2021cites this paper
• PFKFB3: A Potential Key to Ocular Angiogenesis

  2021cites this paper
• TRIM32 inhibits the proliferation and migration of pulmonary artery smooth muscle cells through the inactivation of PI3K/Akt pathway in pulmonary arterial hypertension

  2021cites this paper
• Circular RNA-HIPK3 regulates human pulmonary artery endothelial cells function and vessel growth by regulating microRNA-328-3p/STAT3 axis

  2021cites this paper
• Sex Differences in Pulmonary Arterial Hypertension

  2021cites this paper
• Transforming Growth Factor β1 Increases Expression of Contractile Genes in Human Pulmonary Arterial Smooth Muscle Cells by Potentiating Sphingosine-1-Phosphate Signaling

  2021cites this paper
• Acetazolamide Improves Right Ventricular Function and Metabolic Gene Dysregulation in Experimental Pulmonary Arterial Hypertension

  2021cites this paper
• Aspirin ameliorates pulmonary vascular remodeling in pulmonary hypertension by dampening endothelial-to-mesenchymal transition.

  2021cites this paper
• Potential of C‐X‐C motif chemokine ligand 1/8/10/12 as diagnostic and prognostic biomarkers in idiopathic pulmonary arterial hypertension

  2021influential citation
• Naringin Ameliorates Monocrotaline-Induced Pulmonary Arterial Hypertension Through Endothelial-To-Mesenchymal Transition Inhibition

  2021cites this paper
• Endothelial FGF signaling is protective in hypoxia-induced pulmonary hypertension.

  2021cites this paper
• CTRP9 Mitigates the Progression of Arteriovenous Shunt-Induced Pulmonary Artery Hypertension in Rats

  2021cites this paper
• Pathologic role of peptidyl-prolyl isomerase Pin1 in pulmonary artery remodeling

  2021influential citation
• Upregulation of IRF9 Contributes to Pulmonary Artery Smooth Muscle Cell Proliferation During Pulmonary Arterial Hypertension

  2021influential citation
• Spontaneous Pulmonary Hypertension Associated With Systemic Sclerosis in P‐Selectin Glycoprotein Ligand 1–Deficient Mice

  2020cites this paper
• Long non-coding RNA PVT1 promotes proliferation and migration of pulmonary smooth muscle cells in pulmonary arterial hypertension through miR-140-5p/Fxr1 axis

  2020cites this paper
• Circ-calm4 Serves as an miR-337-3p Sponge to Regulate Myo10 (Myosin 10) and Promote Pulmonary Artery Smooth Muscle Proliferation

  2020cites this paper
• Role of Farnesoid X Receptor in the Pathogenesis of Respiratory Diseases

  2020cites this paper
• Gene and protein-based therapies for improving cardiac performance and regeneration

  2020cites this paper
• Magnesium lithospermate B ameliorates hypobaric hypoxia-induced pulmonary arterial hypertension by inhibiting endothelial-to-mesenchymal transition and its potential targets.

  2020cites this paper
• The beneficial effects of angiotensin-converting enzyme II (ACE2) activator in pulmonary hypertension secondary to left ventricular dysfunction

  2020cites this paper
• Therapeutic Benefit of the Association of Lodenafil with Mesenchymal Stem Cells on Hypoxia-induced Pulmonary Hypertension in Rats

  2020cites this paper
• Dihydroartemisinin Attenuates Pulmonary Hypertension via Inhibition of Pulmonary Vascular Remodeling in Rats.

  2020cites this paper
• LncRNAs and circular RNAs as endothelial cell messengers in hypertension: mechanism insights and therapeutic potential

  2020cites this paper
• NLRC3 inhibits PDGF‐induced PASMCs proliferation via PI3K‐mTOR pathway

  2020cites this paper
• New Insights into the Implication of Mitochondrial Dysfunction in Tissue, Peripheral Blood Mononuclear Cells, and Platelets during Lung Diseases

  2020cites this paper
• Endothelial to Mesenchymal Transition in the Cardiogenesis and Cardiovascular Diseases

  2019cites this paper
• Pulmonary Hypertension

  2019cites this paper
• Clinical implications of idiopathic pulmonary arterial hypertension phenotypes defined by cluster analysis.

  2019cites this paper
• KLF4/Ch25h axis activated by metformin suppresses EndoMT in human umbilical vein endothelial cells.

  2019cites this paper
• Hot topics in the mechanisms of pulmonary arterial hypertension disease: cancer-like pathobiology, the role of the adventitia, systemic involvement, and right ventricular failure

  2019cites this paper
• Systematic Elucidation of the Mechanism of Genistein against Pulmonary Hypertension via Network Pharmacology Approach

  2019cites this paper
• Mechanism of action of Profilin-1 and Fibulin-3 in vascular remodeling in hypertensive rats.

  2019cites this paper
• Vimentin regulates Notch signaling strength and arterial remodeling in response to hemodynamic stress

  2019cites this paper